Liraglutide: Weight loss injection is effective in children aged 6-11, study reports

The weight loss injection liraglutide, branded as Saxenda, effectively reduced body mass index (BMI) in children and was more effective than lifestyle interventions in a small phase 3 trial involving 82 children.1The study, published in the New England Journal of Medicine and funded by the manufacturer Novo Nordisk, saw children aged 6-11 randomly allocated in a 2:1 ratio to either the liraglutide group (a 3 mg, once daily injection) or the placebo plus lifestyle intervention group.The participants were tracked over a 56 week treatment period, with researchers assessing changes in their body weight and BMI. A BMI reduction of at least 5% occurred in 46% of the children in the liraglutide group but in only 9% of participants in the placebo group (adjusted odds ratio 6.3 (95% confidence interval 1.4 to 28.8); P=0.02).Recent data from NHS England show that more than one in five (21.3%) of 4-5 year olds and…
Read Original Article: Liraglutide: Weight loss injection is effective in children aged 6-11, study reports »